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ABSTRACT
Introduction: Patients with atopic dermatitis
(AD) have a greater risk of conjunctivitis and
other ocular surface disorders than the general
population. We evaluated the burden of ocular
surface disorders and related symptoms prior to
treatment initiation in adults with moderate-to-
severe AD.
Methods: Patients were enrolled in a random-
ized, placebo-controlled, double-blinded,
phase 3 trial of dupilumab administered with
concomitant topical corticosteroids. At the
beginning of the screening period, all enrolled
patients completed a survey of ocular disorder
diagnoses received in the past year; at baseline,
patients completed a survey of frequency and
severity of ocular symptoms (discomfort, itch-
ing, redness, and tearing) experienced in the
past month.
Results: A total of 712 of 740 patients enrolled
in the trial provided responses to the survey. At
screening, 286 of 740 patients (38.6%) reported
having at least one ocular disorder in the past
year. At baseline, 499 of 712 respondents
(70.1%) reported having at least one symptom
within the past month. Of these patients, 4.4%,
6.0%, 5.5%, and 4.4%, respectively, reported
having discomfort, itching, redness, and tearing
all of the time. Mild discomfort, itching, red-
ness, and tearing were reported by 26.1%,
33.7%, 30.8%, and 31.6% of patients, respec-
tively, while 7.3%, 7.7%, 6.2%, and 4.2%,
reported severe discomfort, itching, redness,
and tearing, respectively.
Conclusions: These data demonstrate a high
burden of ocular surface disorders and related
symptoms in a population of adults with mod-
erate-to-severe AD. Dermatologists should be
aware of increased incidence of these disorders
in AD and query their patients for signs and
symptoms of eye disease.
ClinicalTrials.gov Registration Number: NCT0
2260986.
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Key Summary Points
Why carry out this study?
Patients with atopic dermatitis (AD) have a
greater risk of conjunctivitis and other
ocular surface disorders than the general
population.
We evaluated the burden of ocular surface
disorders and related symptoms prior to
treatment initiation with dupilumab in
adults with moderate-to-severe AD
enrolled in a randomized, placebo-
controlled, double-blinded phase 3 trial of
dupilumab administered with
concomitant topical corticosteroids.
What was learned from the study?
These data demonstrate a high burden of
ocular surface disorders and related
symptoms in a population of adults with
moderate-to-severe AD.
Dermatologists should be aware of
increased incidence of these disorders in
AD and query their patients for signs and
symptoms of eye disease.
DIGITAL FEATURES
This article is published with digital features to
facilitate understanding of the article. You can
access the digital features on the article’s asso-
ciated Figshare page. To view digital features for
this article go to https://doi.org/10.6084/m9.
figshare.12998804.
INTRODUCTION
Patients with atopic dermatitis (AD) have
a greater risk of conjunctivitis and other
ocular surface disorders (e.g., atopic
keratoconjunctivitis [AKC], keratoconus, her-
petic eye disease, and dry eye) than the general
population [1–12]. The prevalence rates of ocu-
lar surface disorders in patients with AD are
high, with studies showing up to 32–42% of
patients with AD reporting eye disease or pre-
scriptions for eye disorders in the past
12 months [1, 5, 6]. Some of these disorders,
such as AKC, may lead to serious eye problems,
impaired vision, or even vision loss [3, 4, 9].
Incidence of ocular surface disorders increases
with AD severity and factors related to AD
severity, including elevated circulating levels of
IgE, thymus and activation-regulated chemo-
kine, and eosinophils [1, 6, 13].
To provide further information on the
prevalence and severity of these disorders, par-
ticularly in patients with moderate-to-severe
AD, we evaluated the burden of ocular surface
disorders and related symptoms prior to treat-
ment initiation in adults with moderate-to-
severe AD enrolled in a phase 3 trial of
dupilumab.
METHODS
LIBERTY AD CHRONOS (NCT02260986) was a
randomized, placebo-controlled, double-blin-
ded, phase 3 trial of dupilumab administered
with concomitant topical corticosteroids [14].
Detailed patient eligibility criteria were previ-
ously published [14]. In brief, patients were
eligible to enroll in CHRONOS if they were at
least 18 years of age, and had chronic moderate-
to-severe AD, inadequate response to medium-
to high-potency topical corticosteroids (with or
without concomitant topical calcineurin inhi-
bitors) within 6 months before screening, an
Investigator’s Global Assessment Score of at
least 3 (on a scale of 0–4, where 3 was moderate
and 4 was severe), and an Eczema Area and
Severity Index score of at least 16 at screening
and baseline.
At the beginning of the 35-day screening
period, patients completed a survey of ocular
disorder diagnoses received in the past year. At
baseline, they completed a survey of frequency
and severity of ocular symptoms (itching,
1416 Dermatol Ther (Heidelb) (2020) 10:1415–1421
tearing, redness, and discomfort) experienced in
the past month.
The number and proportion of patients at
screening who reported ocular disorder diag-
noses in the past year, and the number and
proportion of patients at baseline reporting
frequency and severity of symptoms, were ana-
lyzed using descriptive statistics, based on the
number of patients who provided responses to
the survey.
The study was conducted in accordance with
the provisions of the Declaration of Helsinki,
the International Conference on Harmonisa-
tion Good Clinical Practice guideline, and
applicable regulatory requirements. The proto-
col was reviewed and approved by institutional
review boards/ethics committees at all study
sites. An independent data monitoring com-
mittee monitored patient safety. All patients
provided signed written informed consent.
RESULTS
Of the 740 patients enrolled in CHRONOS, 712
provided responses to the survey. At screening,
286 of 740 patients (38.6%) reported having at
least one ocular disorder in the past year.
Among the 712 respondents to the survey, the
most common ocular disorder reported in the
past year was dry eye (20.5% of patients), while
the least common disorder reported was kera-
toconus (2.1% of patients) (Table 1). Eighty-
seven patients (12.2%) reported AKC, a poten-
tially serious ocular disorder, in the past year
(Table 1).
Of the 712 respondents to the survey, 499
patients (70.1%; comprising 67.4% of all
enrolled patients) reported having at least one
symptom within the past month at baseline. A
total of 47.9%, 65.0%, 53.8%, and 49.9% of
survey respondents, respectively, reported
symptoms of discomfort, itching, redness, and
tearing in the past month (Table 2). Of these
patients, few reported having symptoms all of
the time (4.4% [discomfort], 6.0% [itching],
5.5% [redness], and 4.4% [tearing]) (Table 2).
Mild symptoms of discomfort, itching, redness,
and tearing were reported by 26.1%, 33.7%,
30.8%, and 31.6% of patients, respectively
(Table 2). Fewer patients (15.0%, 22.6%, 15.3%,
and 12.5%, respectively) reported moderate
Table 1 Screening: ocular surface disorders during the past year
Screening question Yes No I don’t know Missing
Responded to survey, n/N (%) 712/740 (96.2) 28/740 (3.8) – –
Reported C 1 eye disorder in the past year 286/740 (38.6) – – –
Do you have or have you had, n1 (%)a
AKC 87 (12.2) 523 (73.5) 101 (14.2) 1 (0.1)
Dry eye 146 (20.5) 533 (74.9) 33 (4.6) 0
HSV of the eye 30 (4.2) 650 (91.3) 32 (4.5) 0
Keratoconus 15 (2.1) 609 (85.5) 87 (12.2) 1 (0.1)
Perennial allergic conjunctivitis 107 (15.0) 524 (73.6) 81 (11.4) 0
Rosacea of the eye 19 (2.7) 650 (91.3) 43 (6.0) 0
AKC atopic keratoconjunctivitis, HSV herpes simplex virus infection, N number of patients enrolled in the study, n number
of patients who responded to the survey, n1 number of patients with given response
a The percentage is the number of patients with a given response divided by the total number of patients who responded to
the survey; patients may have had more than one ocular disorder diagnosed in the past year
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symptoms of discomfort, itching, redness, and
tearing; and only 7.3%, 7.7%, 6.2%, and 4.2%,
respectively, reported severe symptoms
(Table 2).
DISCUSSION
This survey demonstrated a substantial burden
of ocular surface disorders within the past year
in patients with moderate-to-severe AD that was
inadequately controlled with topical medica-
tions. Most patients reported having at least one
ocular symptom within the past month at
baseline, and a substantial proportion of
symptoms were moderate to severe. The burden
of ocular surface disorders in this patient pop-
ulation is consistent with other studies
demonstrating a substantially greater incidence
of ocular surface disorders among patients with
type 2 inflammatory disorders, such as AD,
asthma, and rhinosinusitis, compared with the
general population [1–12].
Previous studies have demonstrated an
association of AD severity with increased risk of
ocular disorders [1, 6, 13]. Although the burden
of ocular disorders has been demonstrated to be
high in patients with AD compared with the
general population [1–12], there is also an
association of AD with other type 2 inflamma-
tory comorbidities such as allergies, asthma,
and rhinitis, and in turn these type 2 inflam-
matory diseases are also associated with
increased incidence of ocular disorders [15, 16].
Therefore, it is difficult to identify the relative
contributions of AD and other associated type 2
inflammatory disorders to comorbid ocular
diseases.
Some ocular disorders associated with AD,
such as AKC, are potentially serious and may
have an impact on vision, and, therefore,
require ophthalmic assessment and treatment
[1, 3, 4, 9]. Given the demonstrated association
of ocular diseases with AD, it is important to
increase awareness of the burden, signs and
Table 2 Baseline: frequency and severity of ocular symptoms during the past month









None of the time 371 (52.1) 249 (35.0) 329 (46.2) 357 (50.1)
Some of the time 186 (26.1) 248 (34.8) 216 (30.3) 219 (30.8)
Half of the time 61 (8.6) 80 (11.2) 57 (8.0) 55 (7.7)
Most of the time 63 (8.8) 92 (12.9) 71 (10.0) 50 (7.0)
All of the time 31 (4.4) 43 (6.0) 39 (5.5) 31 (4.4)
Any of the timeb 341 (47.9) 463 (65.0) 383 (53.8) 355 (49.9)
Severity of symptom
None 367 (51.5) 256 (36.0) 340 (47.8) 368 (51.7)
Mild 186 (26.1) 240 (33.7) 219 (30.8) 225 (31.6)
Moderate 107 (15.0) 161 (22.6) 109 (15.3) 89 (12.5)
Severe 52 (7.3) 55 (7.7) 44 (6.2) 30 (4.2)
N number of patients who responded to the survey
a The percentage is the number of patients with a given response divided by the total number of patients who responded to
the survey; patients may have had more than one symptom in the past month
b Any of the time comprises some, half, most, or all of the time for a particular symptom; patients may have had more than
one symptom at the same time
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symptoms, and management guidelines for
ocular disease associated with AD among der-
matologists [17, 18].
Limitations of this survey include a popula-
tion comprised of patients who were screened
and enrolled in a clinical trial, which may not
be representative of all patients with moderate-
to-severe AD; however, this is a limitation of all
randomized clinical trials. The survey is a non-
validated instrument, and it is possible that
some patients may not have understood the
medical terms of the questionnaire. Survey data
for diagnoses are subject to recall bias; symptom
data may be more reliable, as they reflect
patient experience within the previous month.
CONCLUSION
These data demonstrate a high burden of ocular
surface disorders and related symptoms in a
population of adults with moderate-to-severe
AD. Dermatologists should be aware of
increased incidence of these disorders in
patients with AD and query their patients for
signs and symptoms of eye disease.
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